Pandorum Technologies Secures $18M Series B to Advance Global Regenerative Medicine

Bengaluru-based biotech startup Pandorum Technologies has successfully raised $18 million in a Series B funding round, marking a major milestone for one of India’s leading ventures in regenerative medicine and programmable tissue therapies. The round was led by Protons Corporate with participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family, among others.

This latest funding round will accelerate Pandorum’s clinical development efforts, expand manufacturing capabilities, and strengthen global operational reach into key markets including the United States, Japan, and the Middle East.

Strong Backing for Regenerative Medicine Innovation

Pandorum’s biotech platform focuses on programmable, exosome-based regenerative therapies, which leverage biological signals from engineered cell vesicles to restore tissue health, counter inflammation, and potentially reverse degenerative conditions.

The company’s lead therapy candidate, Kuragenx, has already received U.S. FDA Orphan Drug Designation for the treatment of rare ocular surface diseases such as Neurotrophic Keratitis and Stevens-Johnson Syndrome. This designation can support expedited regulatory pathways and greater investment confidence.

Utilizing the Capital for Global Scale and Clinical Advancement

According to leadership, the newly raised capital will be deployed for:

• Accelerating clinical trials for programmable regenerative therapies
• Scaling manufacturing through distributed infrastructure in the U.S., Europe, and Asia-Pacific
• Expanding regulatory readiness to navigate multiple global markets
• Advancing systemic treatments for lung, liver, and neurological disorders beyond ophthalmology

Pandorum’s distributed manufacturing strategy includes a key partnership with AGC Biologics to serve the U.S. and European markets, and a collaboration with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to support the Asia-Pacific region.

The Science Behind the Therapies

Pandorum’s approach integrates biology, engineering, and computation to create therapies that can reprogram pathological tissue states, such as inflammation or fibrosis, back toward functional recovery. The technology is grounded in “programmable exosome” platforms tiny biological carriers that can influence cell behavior and promote healing.

The company also collaborates with world-renowned clinicians and researchers to support clinical translation, including partnerships with experts from hospitals and research institutions in the U.S. and India.

Growing Ecosystem and Strategic Partnerships

Pandorum’s vision aligns with India’s broader biotech growth story. As regenerative medicine and deep science innovation attract global investment, startups like Pandorum are increasingly recognized as contributors to the country’s ambition to build a $300 billion bioeconomy by 2030.

Strategic collaborations, such as the manufacturing partnership with Nucelion Therapeutics, reinforce India’s capacity to support cutting-edge biologic production. This integration of local and global expertise enhances regulatory alignment and prepares Pandorum for wider regional distribution.

Leadership and Legacy

Founded in 2011 by Dr Tuhin Bhowmick and Arun Chandru, Pandorum has steadily grown from a deep-science startup into a clinical-stage biotech innovator. The team’s decades of research experience underpins the company’s proprietary technology platform and long-term strategy.

Previous funding rounds, including an earlier $11 million investment, helped lay the groundwork for Pandorum’s tissue engineering programs and research into bio-printed tissues.

The Promise and Challenges Ahead

While the $18 million Series B round represents a substantial vote of confidence from global investors, the journey ahead involves navigating complex clinical and regulatory pathways. Exosome therapies, though promising, operate in a tightly regulated environment. No exosome-based treatment has yet received full FDA approval, and companies in this space must meet stringent safety, efficacy, and manufacturing quality standards.

Nevertheless, Pandorum’s strategic focus, technological depth, and global partnerships position it to be a leader in the regenerative medicine sector.

Why Pandorum’s Growth Matters

Pandorum’s success underscores a new era for Indian biotech startups one where deep science ventures can attract international capital, compete on the global stage, and address real patient needs with breakthrough therapies. The company’s work has implications far beyond corneal conditions, with potential applications in treating inflammation, fibrosis, organ degeneration, and systemic tissue repair.